IRLAB THERAPEUTICS AB

IRLAB's mesdopetam IND accepted by the US FDA

Retrieved on: 
Thursday, October 1, 2020
Health, Drug Safety, Organ systems, Clinical research, Levodopa-induced dyskinesia, Pharmaceutical industry, Investigational New Drug, Dyskinesia, Parkinson's disease, Food and Drug Administration, New Drug Application

STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB's investigational new drug application (IND) for the drug candidate mesdopetam (IRL790).

Key Points: 
  • STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB's investigational new drug application (IND) for the drug candidate mesdopetam (IRL790).
  • The planned Phase IIb/III study for mesdopetam will thus include hospitals and enrol patients in the US and Europe.
  • Mesdopetam is in development for the treatment of levodopa-induced dyskinesias in Parkinson's disease, PD-LIDs, with the objective to increase daily good ON-time.
  • The FDA clearance of the IND is a quality stamp on the mesdopetam project and validates mesdopetam as a safe and tolerable drug candidate.

IRLAB's mesdopetam IND accepted by the US FDA

Retrieved on: 
Thursday, October 1, 2020
Health, Drug Safety, Organ systems, Clinical research, Levodopa-induced dyskinesia, Pharmaceutical industry, Investigational New Drug, Dyskinesia, Parkinson's disease, Food and Drug Administration, New Drug Application

STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB's investigational new drug application (IND) for the drug candidate mesdopetam (IRL790).

Key Points: 
  • STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB's investigational new drug application (IND) for the drug candidate mesdopetam (IRL790).
  • The planned Phase IIb/III study for mesdopetam will thus include hospitals and enrol patients in the US and Europe.
  • Mesdopetam is in development for the treatment of levodopa-induced dyskinesias in Parkinson's disease, PD-LIDs, with the objective to increase daily good ON-time.
  • The FDA clearance of the IND is a quality stamp on the mesdopetam project and validates mesdopetam as a safe and tolerable drug candidate.

IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market

Retrieved on: 
Wednesday, September 23, 2020
Finance, Economy of New York City, NASDAQ, Economy of Europe, Money, Nasdaq First North, Nasdaq Stockholm, Energy in Europe, Economy of London

STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- IRLAB Therapeutics AB ("IRLAB" or the "Company") today announced that Nasdaq Stockholm's listing committee on September 22, 2020 has approved IRLAB's application for admission to trading of the Company's shares of series A on Nasdaq Stockholm Main Market.

Key Points: 
  • STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- IRLAB Therapeutics AB ("IRLAB" or the "Company") today announced that Nasdaq Stockholm's listing committee on September 22, 2020 has approved IRLAB's application for admission to trading of the Company's shares of series A on Nasdaq Stockholm Main Market.
  • The Company's shares of series A are currently traded on Nasdaq First North Premier Growth Market under the ticker IRLAB A.
  • The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020, and the last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September29, 2020.
  • "The listing of IRLAB on Nasdaq Stockholm Main Market entails increased visibility and transparency and is a quality seal on our organization and operations.

IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market

Retrieved on: 
Wednesday, September 23, 2020
Finance, Economy of New York City, NASDAQ, Economy of Europe, Money, Nasdaq First North, Nasdaq Stockholm, Energy in Europe, Economy of London

STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- IRLAB Therapeutics AB ("IRLAB" or the "Company") today announced that Nasdaq Stockholm's listing committee on September 22, 2020 has approved IRLAB's application for admission to trading of the Company's shares of series A on Nasdaq Stockholm Main Market.

Key Points: 
  • STOCKHOLM, Sept. 23, 2020 /PRNewswire/ -- IRLAB Therapeutics AB ("IRLAB" or the "Company") today announced that Nasdaq Stockholm's listing committee on September 22, 2020 has approved IRLAB's application for admission to trading of the Company's shares of series A on Nasdaq Stockholm Main Market.
  • The Company's shares of series A are currently traded on Nasdaq First North Premier Growth Market under the ticker IRLAB A.
  • The first day of trading on Nasdaq Stockholm Main Market is expected to be Wednesday, September 30, 2020, and the last day of trading on Nasdaq First North Premier Growth Market is expected to be Tuesday, September29, 2020.
  • "The listing of IRLAB on Nasdaq Stockholm Main Market entails increased visibility and transparency and is a quality seal on our organization and operations.

IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe

Retrieved on: 
Wednesday, November 6, 2019
Intellectual property law, Patent offices, Patent law, International Searching and Preliminary Examining Authorities, European Patent Organisation, European Patent Office, United States Patent and Trademark Office, Patent

STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.

Key Points: 
  • STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.
  • The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies.
  • Drug candidates IRL942 and IRL1009 stem from IRLAB's P001 research program and are derived from the proprietary research platform ISP.
  • The US Patent and Trademark Office (USPTO) and its counterpart the European Patent Office (EPO) are the authorities having granted patents for the drug candidates IRL942 and IRL1009.

IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe

Retrieved on: 
Wednesday, November 6, 2019
Intellectual property law, Patent offices, Patent law, International Searching and Preliminary Examining Authorities, European Patent Organisation, European Patent Office, United States Patent and Trademark Office, Patent

STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.

Key Points: 
  • STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced today that drug candidates IRL942 and IRL1009 have been granted composition of matter patents in the US and Europe from respective authorities.
  • The preclinical drug candidates are currently undergoing preparatory steps to meet the regulatory requirements for obtaining permission to conduct clinical phase I studies.
  • Drug candidates IRL942 and IRL1009 stem from IRLAB's P001 research program and are derived from the proprietary research platform ISP.
  • The US Patent and Trademark Office (USPTO) and its counterpart the European Patent Office (EPO) are the authorities having granted patents for the drug candidates IRL942 and IRL1009.